Open AccessProphylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS‑102 plus bevacizumab
Author(s) -
Sawako Tamaki,
Hideki Ishikawa,
Koichi Suzuki,
Yasuaki Kimura,
Ryo Maemoto,
Iku Abe,
Yuhei Endo,
Nao Kakizawa,
Fumiaki Watanabe,
Kazushige Futsuhara,
Masaaki Saito,
Shingo Tsujinaka,
Yasuyuki Miyakura,
Toshiki Rikiyama
Publication year - 2022
Publication title -
molecular and clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.442
H-Index - 7
eISSN - 2049-9469
pISSN - 2049-9450
DOI - 10.3892/mco.2022.2536
Subject(s) - pegfilgrastim , medicine , neutropenia , discontinuation , bevacizumab , filgrastim , febrile neutropenia , adverse effect , surgery , oncology , chemotherapy